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Introduction {#sec005}
============

Acute gastrointestinal bleeding (GIB) in patients who are taking oral anticoagulants is expected to increase as the population ages\[[@pone.0183423.ref001]\]. Endoscopy in this setting is a high-risk procedure\[[@pone.0183423.ref002]--[@pone.0183423.ref004]\] in that it is associated with the potential for rebleeding\[[@pone.0183423.ref004]\]. However, few data are available on the endoscopic and clinical outcomes of patients receiving anticoagulant therapy compared with those who are not\[[@pone.0183423.ref005],[@pone.0183423.ref006]\].

The occurrence of acute GIB during anticoagulant therapy raises several difficulties related to the balance between bleeding risk and thromboembolic risk\[[@pone.0183423.ref002],[@pone.0183423.ref003],[@pone.0183423.ref007]\]. These risks are probably related to patient background, endoscopic results, and anticoagulant management\[[@pone.0183423.ref004],[@pone.0183423.ref006],[@pone.0183423.ref008],[@pone.0183423.ref009]\]. However, which of these actually affect adverse outcomes remains unclear. Importantly, the issues of anticoagulant interruption, heparin bridge, and international normalized ratio (INR) correction during the pre-endoscopic period in the acute GIB setting have not been fully addressed in recent endoscopy guidelines from the United States, Europe, or Asia\[[@pone.0183423.ref002],[@pone.0183423.ref003],[@pone.0183423.ref010]\]. Many gastroenterologists, therefore, likely limit the management of anticoagulated patients to their own experiences.

Recently, direct oral anticoagulants (DOACs) have been approved as alternatives to warfarin\[[@pone.0183423.ref011]\]. While there may have been increasing recognition of GIB risk in patients on DOACs\[[@pone.0183423.ref011]--[@pone.0183423.ref013]\], limited data are available on differences in endoscopic results and adverse outcomes of GIB between DOAC and warfarin users\[[@pone.0183423.ref014]\].

The present study builds upon our previous work\[[@pone.0183423.ref015]\] by adding GIB cases who received oral anticoagulants and newly collecting detailed data on baseline, anticoagulant management, and endoscopic and rebleeding outcomes accordingly. Because only 2%-6% of patients with acute GIB use anticoagulants\[[@pone.0183423.ref016]--[@pone.0183423.ref018]\], we reviewed a large number of GIB patients to (i) determine whether anticoagulated patients with acute GIB have adverse endoscopic and clinical outcomes compared with those not receiving anticoagulants, (ii) elucidate the risk factors for rebleeding and thromboembolism following endoscopy in anticoagulated patients; and (iii) explore differences in the endoscopic and clinical outcomes of GIB between DOACs and warfarin users and between those with upper and lower GI.

Material and methods {#sec006}
====================

Study design, setting, and participants {#sec007}
---------------------------------------

We conducted a retrospective cohort study at the Department of Gastroenterology, National Center for Global Health and Medicine (NCGM), Japan. NCGM is the largest emergency hospital, with 900 beds, in the Tokyo metropolitan area. All clinical and endoscopic data analyzed were extracted from a prospective electronic medical database (MegaOak online imaging system, NEC, Japan) and an electronic endoscopic database (SolemioEndo, Olympus, Japan), both of which contain searchable collection of records into which physicians or nurses prospectively input all clinical findings immediately after clinical evaluation or endoscopy\[[@pone.0183423.ref019],[@pone.0183423.ref020]\]. [Fig 1](#pone.0183423.g001){ref-type="fig"} illustrates the study flow of patient selection.

![Study flow.\
Abbreviation. GIB, gastrointestinal bleeding.](pone.0183423.g001){#pone.0183423.g001}

Between January 2009 and May 2016, we identified 1,483 consecutive patients with signs of acute, continuous, or frequent overt GIB ("hematochezia", "red blood per rectum", "melena", "tarry stool", or "hematemesis") who were managed in hospital. We then reviewed the clinical and endoscopic data for each patient and excluded those who: (1) did not undergo endoscopy (n = 129); (2) had no overt bleeding within 3 days of endoscopy (n = 43); (3) had some missing clinical information (n = 14); or (4) were electively admitted with GIB (n = 39). This left a cohort of 1,267 patients with acute GIB who underwent endoscopy from which we analyzed data for 157 anticoagulated patients and 157 non-anticoagulated patients matched for age, sex, body mass index, outpatient onset, year of diagnosis, presenting shock, hematochezia, hemoglobin level, and drug use (NSAIDs, low-dose aspirin \[LDA\], and other antiplatelets).

The requirement for patient consent was waived because this was a retrospective study that was conducted without invasive procedures and data were anonymized and deidentified by the director of the clinical research division at our institution, who was not involved in this study, before our analysis. This study was approved by the ethics committee of the National Center for Global Health and Medicine (No. 1579) and was conducted in accordance with the provisions of the Declaration of Helsinki.

Comorbidities and medication {#sec008}
----------------------------

We collected data on the following background factors: signs of shock, presenting symptoms, history of GIB, co-morbidities, medications, and laboratory data related to GIB. Use of NSAIDs, LDA, non-aspirin antiplatelet drugs, warfarin, DOACs (dabigatran, rivaroxaban, apixaban and edoxaban), or proton pump inhibitors (PPIs) was defined as use within 1 month before admission. We evaluated 16 comorbidities using the Charlson comorbidity index\[[@pone.0183423.ref021]\]. CHA2DS2-VASc\[[@pone.0183423.ref022]\] and HAS-BLED\[[@pone.0183423.ref023]\] scores were calculated. After an episode of GIB, we collected data on anticoagulant management factors: INR in the pre-endoscopic period and use of reversal agent, heparin bridge, and drug interruption. Reversal agents included vitamin K, FFP, prothrombin complex concentrate (PCC), and recombinant activated factor VIIa. For heparin bridge, patients received prophylactic unfractionated heparin infusion intravenously. Only unfractionated heparin is used in Japan because low-molecular-weight heparin is not covered by the health care insurance system\[[@pone.0183423.ref024]\].

Clinical outcomes {#sec009}
-----------------

The main outcomes of interest were rebleeding and thromboembolism within 90 days of endoscopy. Rebleeding was defined as significant overt bleeding along with unstable vital signs, or the need for a transfusion of ≥ 2 units of packed red blood cells in the first 24 h after onset or endoscopically verified GIB. We defined a thromboembolic event as having acute coronary syndrome, stroke, transient ischemic attack, pulmonary embolism, deep vein thrombosis, or arterial thromboembolism. Workup for thromboembolism included positive computed tomography, magnetic resonance imaging, coronary angiography, ventilation-perfusion scanning, and/or ultrasonography.

Statistics {#sec010}
----------

Categorical data were compared between the groups using the Chi-square test or Fisher's exact test, as appropriate. Continuous data were compared with Wilcoxon's rank-sum test. To determine the predictive factors of clinical outcomes, we conducted univariate logistic regression analysis. Odds ratios (ORs) and 95% confidence intervals (CIs) were estimated. In terms of anticoagulant management factors, we developed 4 types of propensity score for DOAC use, PT-INR (onset) ≥ 2.5, reversal agent use, heparin bridge, and anticoagulant interruption by using a logistic regression model for each treatment that included background factors shown to be different (p\<0.10) between treatment and non-treatment. Then, we conducted a multivariate analysis adjusted for the 4 types of propensity score to estimate the adjusted ORs for DOAC use, PT-INR (onset) ≥ 2.5, reversal agent use, heparin bridge, and anticoagulant interruption for clinical outcomes. A value of P \< 0.05 was considered significant. All statistical analysis was performed using STATA version 14 software (StataCorp, College Station, TX).

Results {#sec011}
=======

Background, endoscopy, and outcomes of anticoagulant users and non-users {#sec012}
------------------------------------------------------------------------

The indications for anticoagulant use were as follows ([Table 1](#pone.0183423.t001){ref-type="table"}): atrial fibrillation (n = 104), valvular replacement or valvular disease (n = 28), history of thromboembolism (n = 75); and ≥ 2 of these indications (n = 63). Baseline characteristics for both groups are shown in [Table 1](#pone.0183423.t001){ref-type="table"}. The two groups were well matched for known risk factors, but compared with non-users, anticoagulated patients had significantly higher CHA2DS2-VASc scores, rates of atrial fibrillation and mechanical valve placement, prothrombin time (PT-INR) level, and use of PPIs. Endoscopic diagnosis or therapy is shown in [Table 1](#pone.0183423.t001){ref-type="table"}: 108 patients (69%) underwent endoscopy within 24 h of onset in each group. Among anticoagulant users and non-users, 46.8% had upper sources and 53.2% had lower sources of GIB. The major cause of the bleeding was peptic ulcer disease for upper GIB and colonic diverticular bleeding for lower GIB. There were no significant differences between the two groups in terms of the rate of early endoscopy, upper or lower GIB, endoscopic diagnosis, endoscopic therapy need, transfusion need, rebleeding or thromboembolism. No endoscopy-related adverse events occurred in either group.

10.1371/journal.pone.0183423.t001

###### Baseline characteristics and outcomes of GIB patients compared between anticoagulant users and matched non-user controls (n = 314).

![](pone.0183423.t001){#pone.0183423.t001g}

  ------------------------------------------------------------------------------------ ----------------------------------- --------------------------------- -------------
  **Characteristic**                                                                   **Anticoagulant users (n = 157)**   **Matched non-users (n = 157)**   **P value**
  Age, years                                                                           75.7 ± 10.6                         74.2 ± 11.5                       0.198
  Age \> 70, years                                                                     118 (75.2)                          117 (74.5)                        0.310
  Male                                                                                 96 (61.2)                           96 (61.2)                         1.000
  BMI ≥ 25, kg/m^2^                                                                    41 (26.1)                           31 (19.8)                         0.179
  Inpatient onset                                                                      44 (28.0)                           33 (21.0)                         0.149
  **Signs or symptoms**                                                                                                                                      
  Shock[^‡^](#t001fn002){ref-type="table-fn"}                                          32 (20.4)                           30 (19.1)                         0.777
  Hematemesis                                                                          25 (15.9)                           34 (21.7)                         0.194
  Tarry stool                                                                          68 (43.3)                           54 (34.4)                         0.105
  Hematochezia                                                                         84 (53.5)                           84 (53.5)                         1.000
  **Comorbidities or past-history**                                                                                                                          
  Metabolic syndrome[^†^](#t001fn003){ref-type="table-fn"}                             122 (77.7)                          115 (73.3)                        0.359
  History of thromboembolism[^††^](#t001fn004){ref-type="table-fn"}                    75 (47.8)                           65 (41.4)                         0.256
  History of GI bleeding                                                               34 (21.7)                           27 (17.2)                         0.318
  Charlson comorbidity index                                                           3.5 ± 2.7                           3.9 ± 3.6                         0.938
  CHA2DS2-VASc score                                                                   2.7 ± 1.1                           2.4 ± 1.1                         **0.023**
  HAS-BLED score                                                                       2.7 ± 1.2                           2.5 ± 1.2                         0.121
  Atrial fibrillation                                                                  104 (66.2)                          7 (4.5)                           \<**0.001**
  Mechanical valve                                                                     21 (13.4)                           0                                 \<**0.001**
  Biological valve                                                                     7 (4.5)                             1 (0.6)                           0.067
  **Baseline laboratory data**                                                                                                                               
  Hemoglobin, g/dl                                                                     10.3 ± 4.6                          9.7 ± 3.2                         0.417
  Platelets, 10^4^/μl                                                                  30.9 ± 148.8                        20.7 ± 9.8                        0.129
  PT-INR                                                                               2.0 ± 1.2                           1.1 ± 0.2                         \<**0.001**
  PT-INR \> 2.5                                                                        36 (22.9)                           10 (6.4)                          \<**0.001**
  Albumin, mg/dl                                                                       3.5 ± 2.4                           3.1 ± 0.8                         0.141
  BUN, mg/dl                                                                           35.0 ± 22.4                         31.9 ± 33.5                       0.101
  Creatinine, mg/dl                                                                    1.3 ± 1.3                           1.7 ± 2.3                         0.196
  **Medications**                                                                                                                                            
  NSAIDs                                                                               25 (15.9)                           25 (15.9)                         1.000
  Low-dose aspirin                                                                     49 (31.2)                           44 (28.0)                         0.537
  Thienopyridine[^¶^](#t001fn005){ref-type="table-fn"}                                 9 (5.7)                             10 (6.4)                          0.813
  Other antiplatelets[^¶^](#t001fn005){ref-type="table-fn"}                            10 (6.4)                            6 (3.8)                           0.305
  Proton-pump inhibitors                                                               78 (50.0)                           41 (26.1)                         \<**0.001**
  **Clinical outcome**                                                                 **Anticoagulant users (n = 157)**   **Matched non-users (n = 157)**   **P value**
  Early endoscopy                                                                      108 (68.8)                          108 (68.8)                        1.00
  Bleeding sources, lower GI tract                                                     85 (54.1)                           82 (52.2)                         0.734
  **Upper source**                                                                                                                                           
   Peptic ulcer disease[\*](#t001fn007){ref-type="table-fn"}                           47 (29.9)                           56 (35.7)                         0.279
   Mallory-Weiss syndrome                                                              6 (3.8)                             7 (4.5)                           0.777
   Post-endoscopic therapy                                                             7 (4.5)                             2 (1.3)                           0.173
   Esophageal ulcer                                                                    4 (2.6)                             2 (1.3)                           0.684
   Angioectasia                                                                        2 (1.3)                             2 (1.3)                           1.000
   Varices (esophagus or stomach)                                                      0                                   3 (1.9)                           0.248
   Other diagnosis[\*\*](#t001fn008){ref-type="table-fn"}                              5 (3.2)                             4 (2.6)                           1.000
  **Lower source**                                                                                                                                           
   Colonic diverticular bleeding                                                       26 (16.6)                           29 (18.5)                         0.656
   Ischemic colitis                                                                    10 (6.4)                            13 (8.3)                          0.516
   Other colitis                                                                       2 (1.3)                             5 (3.2)                           0.448
   Colorectal cancer                                                                   5 (3.2)                             3 (1.9)                           0.723
   Radiation proctitis                                                                 0                                   2 (1.3)                           0.498
   Angioectasia                                                                        7 (4.5)                             1 (0.6)                           0.067
   Rectal ulcer                                                                        7 (4.5)                             8 (5.1)                           1.000
   Inflammatory bowel disease                                                          1 (0.6)                             3 (1.9)                           0.623
   Post-endoscopic therapy                                                             13 (8.3)                            5 (3.2)                           0.052
   Hemorrhoids                                                                         4 (2.6)                             4 (2.6)                           1.000
   Middle GIB                                                                          8 (5.1)                             8 (5.1)                           1.000
   Other diagnosis[\*\*\*](#t001fn009){ref-type="table-fn"}                            2 (1.3)                             0                                 0.498
   Unknown[\*\*\*\*](#t001fn010){ref-type="table-fn"}                                  1 (0.6)                             1 (0.6)                           1.000
  **Endoscopic therapy need**                                                          64 (40.8)                           58 (36.9)                         0.487
   Clipping                                                                            55 (35.0)                           47 (29.9)                         0.335
   Band ligation                                                                       5 (3.2)                             9 (5.7)                           0.413
   Epinephrin injection therapy                                                        3 (1.9)                             3 (1.9)                           1.000
   Hemostatic forceps                                                                  3 (1.9)                             0                                 0.248
   Argon plasma coagulation                                                            6 (3.8)                             4 (2.6)                           0.750
  Interventional radiology need                                                        0                                   1 (0.64)                          1.000
  Surgery need                                                                         1 (0.6)                             2 (1.3)                           1.000
  Transfusion need                                                                     83 (52.9)                           77 (49.0)                         0.498
  Units of Transfusion need                                                            3.7 ± 5.3                           4.5 ± 9.4                         0.708
  **Rebleeding**                                                                       21 (13.4)                           25 (15.9)                         0.523
  **Thromboembolism**                                                                  9 (5.7)                             5 (3.2)                           0.677
   Cardiovascular event                                                                0                                   3 (1.9)                           0.248
   Cerebrovascular event                                                               4 (2.6)                             1 (0.6)                           0.371
   Pulmonary embolism or deep vein thrombosis[^‡‡^](#t001fn006){ref-type="table-fn"}   5 (3.2)                             1 (0.6)                           0.214
  ------------------------------------------------------------------------------------ ----------------------------------- --------------------------------- -------------

Values in parentheses are percentages. Values presented with a plus/minus sign are means ± SD. Bold values indicate statistical significance at P \< 0.05.

^‡^Shock was defined as decrease in systolic blood pressure to \< 90 mmHg, paleness, cold sweats, dizziness, syncope, or unconsciousness.

^†^Metabolic syndrome was a clustering of ≥ 2 of the 4 following medical conditions: abdominal (central) obesity, hypertension, diabetes mellitus, and dyslipidemia.

^††^History of thromboembolism was defined as the presence of acute coronary syndrome, stroke, transient ischemic attack, pulmonary embolism, deep vein thrombosis, or arterial thromboembolism.

^¶^Thienopyridine refers to the use of clopidogrel, prasugrel, ticagrelor, and ticlopidine. Other antiplatelets were cilostazol, dipyridamole, sarpogrelate hydrochloride, ethyl icosapentate, dilazep, limaprost, and beraprost.

^‡‡^Deep vein thrombosis occurred in 1 anticoagulant user and in 1 control.

\*Peptic ulcer disease (n = 103) included gastric ulcer (n = 79) and duodenal ulcer (n = 26), and 2 patients had both gastric and duodenal ulcer. Five of the patients with gastric ulcer disease were subsequently identified as having gastric cancer based on histopathology.

\*\*Other diagnosis of upper GIB included pancreatic cancer gastrointestinal invasion (n = 3), aneurysmal rupture to the stomach (n = 1), submucosal tumor of the stomach (n = 2), and bleeding from gastric polyp (n = 3).

\*\*\*Other diagnosis of lower GIB bleeding was bleeding from colonic polyp (n = 2).

\*\*\*\*Unknown source of bleeding (n = 2) was defined as a lesion where upper endoscopy and colonoscopy and/or capsule endoscopy or double-balloon endoscopy did not reveal the bleeding source.

Abbreviations: BMI, body mass index; PT-INR, prothrombin time-international normalized ratio; CHA2DS2-VASc, Congestive heart failure, Hypertension, Age ≥ 75, Diabetes mellitus, Stroke, Vascular disease, Sex female; HAS-BLED, hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, labile international normalized ratios (INR), elderly, drugs/alcohol concomitantly; BUN, blood urea nitrogen; NSAIDs, non-steroidal anti-inflammatory drugs.

Risk factors for rebleeding and thromboembolism in anticoagulated patients {#sec013}
--------------------------------------------------------------------------

Factors associated with outcomes are shown in Tables [2](#pone.0183423.t002){ref-type="table"}--[4](#pone.0183423.t004){ref-type="table"}. Significant predictors of rebleeding were found to be presenting shock, higher comorbidity index (including chronic kidney disease), platelet count \< 10 (10^4^/μl), and low-dose aspirin use at admission but not HAS-BLED score ([Table 2](#pone.0183423.t002){ref-type="table"}). No significant predictors of thromboembolic event were found. No associations were found between any of the endoscopic factors (endoscopy timing, bleeding site, etiology, and therapy) and any of the outcomes ([Table 3](#pone.0183423.t003){ref-type="table"}). INR level at onset or pre-endoscopy did not predict rebleeding, but INR level at onset was a significant predictor of thromboembolism ([Table 4](#pone.0183423.t004){ref-type="table"}). No significant difference in rebleeding rate was seen between INR \< 2.5 and ≥ 2.5, but INR ≥ 2.5 at onset was a predictor of thromboembolism. The difference in INR value between onset and pre- or post-endoscopy was significantly associated with thromboembolism but not rebleeding. Reversal agent use was significantly associated with thromboembolism but not rebleeding. Heparin bridging was not significantly associated with rebleeding or thromboembolism. All thromboembolic events occurred in anticoagulant interrupted patients before endoscopy. In patients without reversal agent use, heparin bridge, or anticoagulant interruption, there was only one rebleeding event and no thromboembolic events.

10.1371/journal.pone.0183423.t002

###### Patient background factors associated with rebleeding and thromboembolism in anticoagulant users with acute GI bleeding (n = 157).

![](pone.0183423.t002){#pone.0183423.t002g}

  ------------------------------------------------------------------- -------------------------------- ------------------------------------------------------ ----------- ------------------------------------ ------------------------------------------------------ ------------------------------------------
  **Factor**                                                          **Rebleeding event/ no event**   **Odds ratio (95%CI)**                                 **P**       **Thromboembolic event/ no event**   **Odds ratio (95%CI)**                                 **P**
  Age, years                                                          77.1± 11.5/ 75.5 ± 10.4          1.0 (1.0--1.1)                                         0.507       70.7 ± 10.9/ 76.0 ± 10.5             0.9 (0.9--1.0)                                         0.148
  Male                                                                13 (61.9)/ 83 (61.0)             1.0 (0.4--2.7)                                         0.939       7 (77.8)/ 89 (60.1)                  2.3 (0.5--11.6)                                        0.304
  BMI ≥ 25, kg/m^2^                                                   5 (23.8)/ 36 (26.5)              0.9 (0.3--2.5)                                         0.796       3 (33.3)/ 38 (25.7)                  1.4 (0.3--6.1)                                         0.613
  In-patient onset                                                    6 (28.6)/ 38 (27.9)              1.0 (0.4--2.9)                                         0.952       2 (22.2)/ 42 (28.4)                  0.7 (0.1--3.6)                                         0.691
  Shock                                                               8 (38.1)/ 24 (17.7)              2.9 (1.1--7.7)                                         **0.036**   3 (33.3)/ 29 (19.6)                  2.1 (0.5--8.7)                                         0.329
  Hematemesis                                                         3 (14.3)/ 22 (16.2)              0.9 (0.2--3.2)                                         0.826       3 (33.3)/ 22 (14.9)                  2.9 (0.7--12.3)                                        0.157
  Tarry stool                                                         8 (38.1)/ 60 (44.1)              0.8 (0.3--2.0)                                         0.605       5 (55.6)/ 63 (42.6)                  1.7 (0.4--6.5)                                         0.449
  Hematochezia                                                        13 (61.9)/ 71 (52.2)             1.5 (0.6--3.8)                                         0.409       3 (33.3)/ 81 (54.7)                  0.4 (0.1--1.7)                                         0.224
  Metabolic syndrome[^†^](#t002fn003){ref-type="table-fn"}            16 (76.2)/ 106 (77.9)            0.9 (0.3--2.7)                                         0.858       6 (66.7)/ 106 (78.4)                 0.6 (0.1--2.3)                                         0.418
  History of thromboembolism[^††^](#t002fn004){ref-type="table-fn"}   12 (57.1)/ 63 (46.3)             1.5 (0.6--3.9)                                         0.358       6 (66.7)/ 69 (46.6)                  2.3 (0.6--9.5)                                         0.254
  History of GI bleeding                                              5 (23.8)/ 29 (21.3)              1.2 (0.4--3.4)                                         0.797       0/ 34 (23.0)                         0.3 (0--1.8)[\*](#t002fn002){ref-type="table-fn"}      0.208
  Liver cirrhosis                                                     1 (5.3)/ 4 (2.9)                 1.9 (0.2--17.6)                                        0.588       0/ 5 (3.4)                           NA[^†^](#t002fn003){ref-type="table-fn"}               NA[^†^](#t002fn003){ref-type="table-fn"}
  Chronic kidney disease                                              3 (15.8)/ 5 (3.6)                5.0 (1.1--22.9)                                        **0.039**   1 (12.5)/ 7 (4.7)                    2.9 (0.3--26.9)                                        0.349
  Charlson comorbidity index                                          4.8 ± 3.0/ 3.3 ± 2.6             1.2 (1.0--1.4)                                         **0.024**   4.3 ± 4.3/ 3.5 ± 2.6                 1.1 (0.9--1.4)                                         0.362
  CHA2DS2-VASc                                                        2.7 ± 0.8/ 2.7 ± 1.1             1.0 (0.7--1.5)                                         0.970       2.1 ± 0.9/ 2.7 ± 1.1                 0.6 (0.3--1.1)                                         0.114
  HAS-BLED score                                                      3.0 ± 1.2/ 2.6 ± 1.2             1.4 (0.9--2.0)                                         0.135       2.7 ± 1.0/ 2.7 ± 1.2                 1.0 (05--1.8)                                          0.941
  Atrial fibrillation                                                 12 (57.1)/ 92 (67.7)             0.6 (0.3--1.6)                                         0.346       5 (55.6)/ 99 (66.9)                  0.6 (0.2--2.4)                                         0.489
  Mechanical valve                                                    3 (14.3)/ 18 (13.2)              1.1 (0.3--4.1)                                         0.895       2 (22.2)/ 19 (12.8)                  1.9 (0.4--10.0)                                        0.429
  **Factor**                                                          **Rebleeding event/ no event**   **Odds ratio (95%CI)**                                 **P**       **Thromboembolic event/ no event**   **Odds ratio (95%CI)**                                 **P**
  Biological valve                                                    0/ 7 (5.2)                       0.7 (0--4.6)[\*](#t002fn002){ref-type="table-fn"}      0.717       0 / 7 (4.7)                          1.7 (0--12.8)[\*](#t002fn002){ref-type="table-fn"}     1.000
  Hb \< 7, g/dl                                                       4 (19.1)/ 25 (18.4)              1.0 (0.3--3.4)                                         0.942       4 (44.4)/ 25 (16.9)                  3.9 (0.9--15.7)                                        0.052
  Platelets \< 10, 10^4^/μl                                           6 (28.6)/ 10 (7.4)               5.0 (1.6--15.8)                                        **0.006**   0/ 16 (10.8)                         0.7 (0--4.6)[\*](#t002fn002){ref-type="table-fn"}      0.739
  Alb \< 3.0, mg/dl                                                   10 (47.6)/ 35 (25.7)             2.6 (1.0--6.7)                                         **0.044**   5 (55.6)/ 40 (27.0)                  3.4 (0.8--13.2)                                        0.080
  BUN \> 20.0, mg/dl                                                  17 (81.0)/ 94 (69.1)             1.9 (0.6--6.0)                                         0.274       7 (77.8)/ 104 (70.3)                 1.5 (0.3--7.4)                                         0.633
  Creatinine \>1.0, mg/dl                                             12 (57.1)/ 65 (47.8)             1.5 (0.6--3.7)                                         0.427       5 (55.6)/ 72 (48.7)                  1.3 (0.3--5.1)                                         0.688
  NSAID use (admission)                                               1 (4.8)/ 24 (17.7)               0.2 (0.03--1.8)                                        0.165       3 (33.3)/ 22 (14.9)                  2.9 (0.7--12.3)                                        0.157
  NSAID interruption                                                  0/ 20 (83.3)                     0.3 (0--9.8)[\*](#t002fn002){ref-type="table-fn"}      0.400       2 (66.7)/ 18 (81.8)                  0.4 (0.03--6.2)                                        0.546
  LDA use (admission)                                                 12 (52.4)/ 38 (27.9)             2.8 (1.1--7.2)                                         **0.029**   4 (44.4)/ 45 (30.4)                  1.8 (0.5--7.1)                                         0.384
  LDA interruption                                                    10 (90.9)/ 32 (84.2)             1.9 (0.2--17.5)                                        0.581       4 (100)/ 38 (84.4)                   0.9 (0.1-+inf)                                         1.000
  Antiplatelet use (admission)                                        3 (14.3)/ 14 (10.3)              1.5 (0.4--5.6)                                         0.586       2 (22.2)/ 15 (10.1)                  2.5 (0.5--13.3)                                        0.272
  Antiplatelet interruption                                           3 (100)/ 13 (92.9)               0.2 (0.001-inf)[\*](#t002fn002){ref-type="table-fn"}   1.000       2 (100)/ 14 (93.3)                   0.1 (0.003-inf)[\*](#t002fn002){ref-type="table-fn"}   1.000
  PPI use (admission)                                                 14 (66.7)/ 64 (47.1)             2.3 (0.9--5.9)                                         0.101       6 (66.7)/ 72 (48.7)                  2.1 (0.5--8.8)                                         0.303
  PPI continuation or start                                           6 (33.3)/ 29 (24.2)              1.6 (0.5--4.6)                                         0.407       1 (11.1)/ 34 (26.4)                  0.3 (0.04--2.9)                                        0.330
  ------------------------------------------------------------------- -------------------------------- ------------------------------------------------------ ----------- ------------------------------------ ------------------------------------------------------ ------------------------------------------

Values in parentheses are percentages. Values presented with a plus/minus sign are means ± SD.

\*Exact logistic regression was performed. Bold values mean statistical significance at P \< 0.05.

^†^There were no patients with outcomes and statistical analysis was not performed.

^††^History of thromboembolism was defined as the presence of acute coronary syndrome, stroke, transient ischemic attack, pulmonary embolism, deep vein thrombosis, or arterial thromboembolism.

Abbreviations: BMI, body mass index; CHA2DS2-VASc, Congestive heart failure, Hypertension, Age ≥ 75, Diabetes mellitus, Stroke, Vascular disease, Sex female; HAS-BLED, hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, labile international normalized ratios (INR), elderly, drugs/alcohol concomitantly; BUN, blood urea nitrogen; NSAID, non-steroidal anti-inflammatory drugs; NA, not applicable; LDA, low-dose aspirin; PPI, proton-pump inhibitors; Inf, infinity.

10.1371/journal.pone.0183423.t003

###### Endoscopic factors associated with rebleeding and thromboembolism in anticoagulant users with acute GI bleeding (n = 157).

![](pone.0183423.t003){#pone.0183423.t003g}

  Factor                          Rebleeding event/ no event   Odds ratio (95%CI)   P       Thromboembolic event/ no event   Odds ratio (95%CI)                                      P
  ------------------------------- ---------------------------- -------------------- ------- -------------------------------- ------------------------------------------------------- -------
  Early endoscopy (≤ 24 h)        13 (61.9)/ 90 (69.9)         0.7 (0.3--1.8)       0.466   5 (55.6)/ 103 (69.6)             0.5 (0.1--2.1)                                          0.384
  Lower GIB vs upper GIB          12 (57.1)/ 73 (53.7)         1.2 (0.5--2.9)       0.767   3 (33.3)/ 82 (55.4)              0.4 (0.1--1.7)                                          0.210
  Peptic ulcer bleeding           4 (19.1)/ 43 (31.6)          0.5 (0.2--1.6)       0.249   4 (44.4)/ 43 (29.1)              2.0 (05--7.6)                                           0.335
  Colonic diverticular bleeding   3 (14.3)/ 23 (16.9)          0.8 (0.2--3.0)       0.763   0/ 26 (17.6)                     0.4 (0.01--2.4)[\*](#t003fn002){ref-type="table-fn"}    0.523
  Received endoscopic therapy     11 (52.4)/ 53 (39.0)         1.7 (0.7--4.3)       0.248   4 (44.4)/ 60 (40.5)              1.2 (0.3--4.5)                                          0.817
  Received endoscopic clipping    8 (38.1)/ 47 (34.6)          1.2 (0.5--3.0)       0.752   3 (33.3)/ 52 (35.1)              0.9 (0.2--3.8)                                          0.912
  Received endoscopic ligation    1 (4.8)/ 4 (2.9)             1.7 (0.2--15.5)      0.661   0/ 5 (3.4)                       1.7 (0.04--13.1)[\*](#t003fn002){ref-type="table-fn"}   0.959

Values in parentheses are percentages. Values presented with a plus/minus sign are means ± SD.

\*Exact logistic regression was performed. Bold values indicate statistical significance at P \< 0.05.

Abbreviation. GIB, gastrointestinal bleeding.

10.1371/journal.pone.0183423.t004

###### Anticoagulant management factors associated with rebleeding and thromboembolism in anticoagulant users with acute GI bleeding (n = 157).

![](pone.0183423.t004){#pone.0183423.t004g}

  Factor                                                                            Rebleeding event/ no event   Odds ratio (95%CI)   P       Thromboembolic event/ no event   Odds ratio (95%CI)                                   P
  --------------------------------------------------------------------------------- ---------------------------- -------------------- ------- -------------------------------- ---------------------------------------------------- -----------
  DOAC use                                                                          5 (23.8)/ 37 (27.2)          0.8 (0.3--2.4)       0.744   1 (11.1)/ 41 (27.1)              0.3 (0.04--2.7)                                      0.298
  PT-INR (onset)                                                                    1.8 ± 0.8/ 1.9 ± 0.8         0.8 (0.4--1.5)       0.517   2.6 ± 1.0/ 1.8 ± 0.7             3.1 (1.4--7.2)                                       **0.008**
  PT-INR (pre-endoscopy)                                                            1.6 ± 0.7/ 1.7 ± 0.7         0.8 (0.4--1.6)       0.568   2.1 ± 1.0/ 1.7 ± 0.7             1.8 (0.8--4.1)                                       0.139
  PT-INR (onset) ≥ 2.5                                                              4 (19.1)/ 32 (23.5)          0.8 (0.2--2.4)       0.650   6 (66.7)/ 30 (20.3)              7.9 (1.9--33.3)                                      **0.005**
  PT-INR (pre-endoscopy) ≥ 2.5                                                      2 (9.5)/ 25 (18.4)           0.5 (0.1--2.1)       0.327   3 (33.3)/ 24 (16.2)              2.6 (0.6--11.0)                                      0.201
  Difference of INR value between admission and pre-endoscopy                       0.2 ± 0.3/ 0.2 ± 0.4         0.9 (0.3--3.1)       0.974   0.5 ± 0.8/ 0.2 ± 0.4             3.7 (1.2--11.3)                                      **0.022**
  Difference of INR value between onset and post-endoscopy                          0.5 ± 0.8/ 0.5 ± 0.7         1.0 (0.5--2.0)       0.897   1.3 ± 1.0/ 0.4 ± 0.7             3.2 (1.5--6.7)                                       **0.002**
  Reversal agent (Vitamin K antagonist) use[^¶^](#t004fn004){ref-type="table-fn"}   4 (19.1)/ 24 (17.7)          1.1 (0.3--3.6)       0.876   4 (44.4)/ 24 (16.2)              4.1 (1.0--16.5)                                      **0.045**
  Heparin bridging                                                                  7 (33.3)/ 42 (30.9)          1.1 (0.4--3.0)       0.822   4 (44.4)/ 45 (30.4)              1.8 (0.5--7.1)                                       0.384
  Anticoagulant interruption before endoscopy                                       19 (90.5)/ 97 (71.3)         3.8 (0.8--17.2)      0.081   9 (100)/ 107 (72.3)              4.7 (0.7-inf)[\*](#t004fn002){ref-type="table-fn"}   0.121
  No reversal agent use, no heparin bridge, or no anticoagulant interruption        1 (4.8)/ 36 (26.5)           0.1 (0.02--1.1)      0.058   0/ 37 (25)                       0.2 (0--1.6)[\*](#t004fn002){ref-type="table-fn"}    0.165

Values in parentheses are percentages. Values presented with a plus/minus sign are means ± SD.

\*Exact logistic regression was performed.

Bold values denote statistical significance at P \< 0.05.

^¶^Twenty-eight of patients received a reversal agent (Vitamin K) intravenously during the peri-endoscopic period; no patients received FFP, prothrombin complex concentrate, or recombinant activated factor VIIa.

Abbreviations: PT-INR, prothrombin time-international normalized ratio; Inf, infinity.

Even after propensity score adjustment, the risk of DOAC use, PT-INR ≥ 2.5 at onset, heparin bridge, or anticoagulant interruption for any of the clinical outcomes remained unchanged compared with univariate analysis. Reversal agent use was not significantly associated with thromboembolism after propensity score adjustment ([Table 5](#pone.0183423.t005){ref-type="table"}).

10.1371/journal.pone.0183423.t005

###### Anticoagulant management factors associated with rebleeding and thromboembolism in GI bleeders after propensity score adjustment (n = 157).

![](pone.0183423.t005){#pone.0183423.t005g}

                                                Propensity score for each treatment   Rebleeding risk           Thromboembolic risk                        
  --------------------------------------------- ------------------------------------- ----------------- ------- ------------------------------------------ ------------------------------------------
  DOAC use                                      0.81 (0.74--0.88)                     0.8 (0.2--2.5)    0.648   0.6 (0.06--5.9)                            0.646
  PT-INR (onset) ≥ 2.5                          0.74 (0.65--0.83)                     0.7 (0.2--2.3)    0.523   7.3 (1.5--35.3)                            **0.013**
  Reversal agent (vitamin K antagonist) use     0.92 (0.87--0.97)                     1.4 (0.3--7.3)    0.722   1.2 (0.2--9.1)                             0.840
  Heparin bridging                              0.77 (0.68--0.85)                     0.8 (0.3--2.3)    0.648   1.3 (0.3--5.8)                             0.767
  Anticoagulant interruption before endoscopy   0.79 (0.71--0.86)                     3.3 (0.7--16.1)   0.081   NA[^†^](#t005fn007){ref-type="table-fn"}   NA[^†^](#t005fn007){ref-type="table-fn"}

Bold values denote statistical significance at P \< 0.05.

To estimate propensity scores, the following logistic regression models were used. For DOAC use, the model included 8 factors shown to be different on univariate analysis (P \< 0.10) between DOAC use and non-use: being elderly (age ≥ 70 years), sex, past history of thromboembolism, CHA2DS2-VASc score, atrial fibrillation, hemoglobin, INR \> 2.5, and low-dose aspirin use.

For INR \> 2.5, the model included 9 factors different on univariate analysis (P \< 0.10) between INR \> 2.5 use and INR ≤ 2.5: being elderly (age ≥ 70 years), sex, past history of thromboembolism, past history of gastrointestinal bleeding, HAS-BLED score, atrial fibrillation, mechanical valve, biological valve, and DOAC use.

For reversal agent (vitamin K antagonist) use, the model included 11 factors different on univariate analysis (P \< 0.10) between reversal agent use and non-use: being elderly (age ≥ 70 years), sex, hematemesis, metabolic syndrome, Charlson comorbidity index score, CHA2DS2-VASc score, atrial fibrillation, mechanical valve, hemoglobin, INR \> 2.5, and DOAC use.

For heparin bridge, the model included 6 factors different on univariate analysis (P \< 0.10) between heparin bridge use and non-heparin bridge: being elderly (age ≥ 70 years), sex, NSAID use, low-dose aspirin use, non-aspirin antiplatelet use, and DOAC use.

For anticoagulant interruption, the model included 9 factors different on univariate analysis (P \< 0.10) between heparin bridge use and non-heparin bridge: being elderly (age ≥ 70 years), sex, BMI ≥ 25, inpatient onset, past history of gastrointestinal bleeding, INR \> 2.5, low-dose aspirin use, non-aspirin antiplatelet use, and DOAC use.

^†^All interrupted patients had thromboembolism and statistical analysis could not be performed.

Abbreviations: PT-INR, prothrombin time-international normalized ratio; DOAC, direct oral anticoagulant.

Subgroup analysis of DOAC and warfarin users {#sec014}
--------------------------------------------

Compared with warfarin users, DOAC users had a significantly higher rate of atrial fibrillation, higher levels of hemoglobin and albumin, lower levels of PT-INR and BUN, a lower rate of LDA use, and a higher rate of lower GIB ([Table 6](#pone.0183423.t006){ref-type="table"}). No significant difference was found in the rate of early endoscopy, other endoscopic diagnosis, or other endoscopic therapy between the groups ([Table 6](#pone.0183423.t006){ref-type="table"}). In terms of clinical outcomes, DOAC users received significantly fewer transfusions than warfarin users, and no significant differences were found in endoscopic therapy need, rebleeding, or thromboembolism between the groups ([Table 6](#pone.0183423.t006){ref-type="table"}).

10.1371/journal.pone.0183423.t006

###### Baseline characteristics and outcomes of GIB compared between direct oral anticoagulant (DOAC) and warfarin users (n = 157).

![](pone.0183423.t006){#pone.0183423.t006g}

  ------------------------------------------------------------------- ------------------------- ------------------------------ -------------
  **Characteristic**                                                  **DOAC users (n = 42)**   **Warfarin users (n = 115)**   **P value**
  Age, years                                                          77.6 ± 7.7                75.0 ± 11.4                    0.385
  Age \> 70, years                                                    34 (81.0)                 84 (73.0)                      0.310
  Male                                                                23 (54.8)                 73 (63.4)                      0.321
  BMI ≥ 25, kg/m^2^                                                   13 (31.0)                 28 (24.4)                      0.404
  Inpatient onset                                                     11 (26.2)                 33 (28.7)                      0.757
  **Signs or symptoms**                                                                                                        
  Shock                                                               6 (14.3)                  26 (22.6)                      0.252
  Hematemesis                                                         4 (9.5)                   21 (18.3)                      0.185
  Tarry stool                                                         19 (45.2)                 49 (42.6)                      0.769
  Hematochezia                                                        25 (59.5)                 59 (51.3)                      0.361
  **Comorbidities or past-history**                                                                                            
  Metabolic syndrome[^†^](#t006fn002){ref-type="table-fn"}            31 (73.8)                 91 (79.1)                      0.478
  History of thromboembolism[^††^](#t006fn003){ref-type="table-fn"}   25 (59.5)                 50 (43.5)                      0.075
  History of GI bleeding                                              11 (26.2)                 23 (20.0)                      0.405
  Charlson comorbidity index                                          3.4 ± 3.0                 3.6 ± 2.6                      0.315
  CHA2DS2-VASc score                                                  2.9 ± 0.9                 2.6 ± 1.1                      0.174
  HAS-BLED score                                                      2.8 ± 1.0                 2.7 ± 1.2                      0.635
  Atrial fibrillation                                                 34 (81.0)                 70 (60.9)                      **0.018**
  Mechanical valve                                                    5 (11.9)                  16 (13.9)                      0.743
  Biological valve                                                    2 (4.8)                   5 (4.4)                        1.000
  **Baseline laboratory data**                                                                                                 
  Hemoglobin, g/dl                                                    10.9 ± 2.9                10.1 ± 5.1                     **0.030**
  Platelets, 10^4^/μl                                                 18.4 ± 6.8                35.5 ± 173.7                   0.827
  PT-INR                                                              1.3 ± 0.3                 2.2 ± 1.3                      \<**0.001**
  PT-INR \> 2.5                                                       3 (7.1)                   33 (28.7)                      **0.005**
  Albumin, mg/dl                                                      3.5 ± 0.6                 3.4 ± 2.8                      **0.003**
  BUN, mg/dl                                                          30.2 ± 27.1               36.7 ± 21.8                    **0.001**
  Creatinine, mg/dl                                                   1.0 ± 0.4                 1.4 ± 1.4                      0.400
  **Medications**                                                                                                              
  NSAIDs                                                              6 (14.3)                  19 (16.5)                      0.735
  Low-dose aspirin                                                    8 (19.1)                  41 (35.7)                      **0.047**
  Thienopyridine                                                      2 (4.7)                   7 (6.1)                        1.000
  Other antiplatelets[^¶^](#t006fn004){ref-type="table-fn"}           1 (2.4                    9 (7.8)                        0.291
  Proton-pump inhibitors                                              23 (54.8)                 55 (47.8)                      0.442
  **Clinical outcome**                                                **DOAC users (n = 42)**   **Warfarin users (n = 115)**   **P value**
  Early endoscopy                                                     31 (73.8)                 77 (67)                        0.412
  Bleeding sources, lower GI tract                                    29 (69.1)                 56 (48.7)                      **0.023**
  **Upper source**                                                                                                             
   Peptic ulcer disease[\*](#t006fn005){ref-type="table-fn"}          9 (21.4)                  38 (33.0)                      0.160
   Mallory-Weiss syndrome                                             2 (4.8)                   5 (4.4)                        1.000
   Post-endoscopic therapy                                            0                         7 (6.1)                        0.191
   Esophageal ulcer                                                   3 (2.6)                   1 (0.9)                        1.000
   Angioectasia                                                       0                         2 (1.7)                        1.000
   Varices (esophagus or stomach)                                     0                         0                              NA
   Other diagnosis[\*\*](#t006fn006){ref-type="table-fn"}             2 (4.8)                   3 (2.6)                        0.610
  **Lower source**                                                                                                             
   Colonic diverticular bleeding                                      8 (19.1)                  18 (15.7)                      0.612
   Ischemic colitis                                                   2 (4.8)                   8 (7.0)                        1.000
   Other colitis                                                      0                         2 (1.7)                        1.000
   Colorectal cancer                                                  0                         5 (4.4)                        0.325
   Radiation proctitis                                                0                         0                              NA
   Angioectasia                                                       3 (7.1)                   4 (3.5)                        0.385
   Rectal ulcer                                                       1 (2.4)                   6 (5.2)                        0.676
   Inflammatory bowel disease                                         0                         1 (0.9)                        1.000
   Post-endoscopic therapy                                            8 (19.1)                  5 (4.4)                        **0.006**
   Hemorrhoids                                                        2 (4.8)                   2 (1.7)                        0.290
   Middle GIB                                                         5 (11.9)                  3 (2.6)                        **0.032**
   Other diagnosis[\*\*\*](#t006fn007){ref-type="table-fn"}           0                         2 (1.7)                        1.000
   Unknown[\*\*\*\*](#t006fn008){ref-type="table-fn"}                 0                         1 (0.9)                        1.000
  **Endoscopic therapy need**                                         18 (42.9)                 46 (40.0)                      0.747
   Clipping                                                           14 (33.3)                 41 (35.7)                      0.787
   Band ligation                                                      4 (9.5)                   1 (0.9)                        **0.018**
   Epinephrin injection therapy                                       0                         2 (6.1)                        0.565
   Hemostatic forceps                                                 0                         3 (2.6)                        0.565
   Argon plasma coagulation                                           0                         6 (5.2)                        0.193
   Combined therapy                                                   0                         6 (5.2)                        0.193
  Interventional radiology need                                       0                         0                              NA
  Surgery need                                                        0                         1 (0.9)                        1.000
  Transfusion need                                                    17 (40.5)                 66 (57.4)                      0.072
  Units of transfusion needed                                         2.2 ± 3.1                 4.3 ± 5.9                      **0.046**
  **Rebleeding**                                                      5 (11.9)                  16 (13.9)                      0.743
  **Thromboembolism**                                                 1 (2.4)                   8 (7.0)                        0.446
  ------------------------------------------------------------------- ------------------------- ------------------------------ -------------

Values in parentheses are percentages. Values presented with a plus/minus sign are means ± SD. Bold values indicate statistical significance at P \< 0.05.

^†^Metabolic syndrome was a clustering of at least two of the four following medical conditions: abdominal (central) obesity, hypertension, diabetes mellitus, and dyslipidemia.

^††^History of thromboembolism was defined as the presence of acute coronary syndrome, stroke, transient ischemic attack, pulmonary embolism, deep vein thrombosis, or arterial thromboembolism.

^¶^Other antiplatelets were cilostazol, dipyridamole, sarpogrelate hydrochloride, ethyl icosapentate, dilazep, limaprost, and beraprost.

\*Peptic ulcer disease (n = 103) included gastric ulcer (n = 79) and duodenal ulcer (n = 26), and 2 patients had both gastric and duodenal ulcer. Five of the patients with gastric ulcer disease were subsequently identified as having gastric cancer based on histopathology.

\*\*Other diagnosis of upper GIB included pancreatic cancer gastrointestinal invasion (n = 3), aneurysmal rupture to the stomach (n = 1), submucosal tumor of the stomach (n = 2), and bleeding from gastric polyp (n = 3).

\*\*\*Other diagnosis of lower GIB bleeding was bleeding from colonic polyp (n = 2).

\*\*\*\*Unknown source of bleeding (n = 2) was defined as a lesion where upper endoscopy and colonoscopy and/or capsule endoscopy or double-balloon endoscopy did not reveal the bleeding source.

Abbreviations: BMI, body mass index; PT-INR, prothrombin time-international normalized ratio; CHA2DS2-VASc, Congestive heart failure, Hypertension, Age ≥ 75, Diabetes mellitus, Stroke, Vascular disease, Sex female; DOAC, direct oral anticoagulant; HAS-BLED, hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, labile international normalized ratios (INR), elderly, drugs/alcohol concomitantly; BUN, blood urea nitrogen; NSAIDs, non-steroidal anti-inflammatory drugs.

Subgroup analysis of patients diagnosed with upper and lower GIB {#sec015}
----------------------------------------------------------------

Compared with lower GI bleeders, there was a significantly higher rate of upper GI bleeders in elderly patients (\> 70 years) and patients with shock, hematemesis, tarry stool, lower hemoglobin and albumin levels, or higher BUN level ([Table 7](#pone.0183423.t007){ref-type="table"}). Upper GI bleeders were associated with a significantly higher rate of early endoscopy, endoscopic therapy need (particularly clipping), and transfusion need ([Table 7](#pone.0183423.t007){ref-type="table"}).

10.1371/journal.pone.0183423.t007

###### Baseline characteristics and outcomes of anticoagulant users compared between upper and lower GI bleeding (n = 157).

![](pone.0183423.t007){#pone.0183423.t007g}

  ------------------------------------------------------------------- ------------------------ ------------------------ -------------
  **Characteristic**                                                  **Upper GIB (n = 72)**   **Lower GIB (n = 85)**   P value
  Age, years                                                          47 (65.3)                71 (83.5)                **0.008**
  Age \> 70, years                                                    73.9±11.2                77.2±9.8                 **0.046**
  Male                                                                48 (56.5)                48 (66.7)                0.192
  BMI ≥ 25, kg/m^2^                                                   21 (24.7)                20 (27.8)                0.662
  Inpatient onset                                                     19 (22.4)                25 (34.7)                0.086
  **Signs or symptoms**                                                                                                 
  Shock[^‡^](#t007fn002){ref-type="table-fn"}                         20 (27.8)                12 (14.1)                **0.034**
  Hematemesis                                                         23 (31.9)                2 (2.4)                  \<**0.001**
  Tarry stool                                                         54 (75.0)                14 (16.5)                \<**0.001**
  Hematochezia                                                        8 (11.1)                 76 (89.4)                \<**0.001**
  **Comorbidities or past history**                                                                                     
  Metabolic syndrome[^†^](#t007fn003){ref-type="table-fn"}            54 (75.0)                68 (80.0)                0.453
  History of thromboembolism[^††^](#t007fn004){ref-type="table-fn"}   33 (45.8)                42 (49.4)                0.655
  History of GI bleeding                                              13 (18.1)                21 (24.7)                0.313
  Charlson comorbidity index                                          55 (76.4)                59 (69.4)                0.329
  CHA2DS2-VASc score                                                  62 (86.1)                78 (91.8)                0.256
  HAS-BLED score                                                      39 (54.2)                49 (57.7)                0.662
  Atrial fibrillation                                                 47 (65.3)                57 (67.1)                0.814
  Mechanical valve                                                    8 (11.1)                 13 (15.3)                0.443
  Biological valve                                                    3 (4.2)                  4 (4.7)                  1.000
  **Baseline laboratory data**                                                                                          
  Hemoglobin, g/dl                                                    8.8±2.9                  11.5±5.4                 \<**0.001**
  Platelets, 10^4^/μl                                                 20.0±9.0                 40.1±202.1               0.224
  PT-INR                                                              2.1±1.3                  1.9±1.1                  0.140
  PT-INR \> 2.5                                                       21 (29.2)                15 (17.7)                0.087
  Albumin, mg/dl                                                      3.1±0.6                  3.8±3.2                  \<**0.001**
  BUN, mg/dl                                                          44.9±25.1                26.6±18.1                \<**0.001**
  Creatinine, mg/dl                                                   1.4±1.5                  1.2±1.0                  0.948
  **Medications**                                                                                                       
  NSAIDs                                                              14 (19.4)                11 (12.9)                0.267
  LDA                                                                 27 (37.5)                22 (25.9)                0.117
  Thienopyridine                                                      3 (4.2)                  6 (7.1)                  0.509
  Other antiplatelets[^¶^](#t007fn005){ref-type="table-fn"}           4 (5.6)                  6 (7.1)                  0.755
  PPIs                                                                32 (44.4)                46 (54.1)                0.227
  **Clinical outcomes**                                               **Upper GIB (n = 72)**   **Lower GIB (n = 85)**   P value
  Early endoscopy                                                     60 (83.3)                48 (56.5)                \<**0.001**
  **Endoscopic therapy need**                                         37 (51.4)                27 (31.8)                **0.013**
   Clipping                                                           34 (47.2)                21 (24.7)                **0.003**
   Band ligation                                                      1 (1.4)                  4 (4.7)                  0.376
   Epinephrin injection therapy                                       3 (4.2)                  0                        0.094
   Hemostatic forceps                                                 1 (1.4)                  2 (2.4)                  1.000
   Argon plasma coagulation                                           2 (2.8)                  4 (4.7)                  0.688
   Combined therapy                                                   4 (5.6)                  2 (2.4)                  0.414
  Interventional radiology need                                       0                        0                        NA
  Surgery need                                                        0                        1 (1.2)                  1.000
  Transfusion need                                                    51 (70.8)                32 (37.7)                \<**0.001**
  Units of Transfusion need                                                                                             
  **Rebleeding**                                                      9 (12.5)                 12 (14.1)                0.767
  **Thromboembolism**                                                 6 (8.3)                  3 (3.5)                  0.303
  ------------------------------------------------------------------- ------------------------ ------------------------ -------------

Values in parentheses are percentages. Values presented with a plus/minus sign are means ± SD. Bold values mean statistical significance at P \< 0.05.

^‡^Shock was defined as decrease in systolic blood pressure to \< 90 mmHg, paleness, cold sweats, dizziness, syncope, or unconsciousness.

^†^Metabolic syndrome was a clustering of ≥ 2 of the 4 following medical conditions: abdominal (central) obesity, hypertension, diabetes mellitus, and dyslipidemia.

^††^History of thromboembolism was defined as the presence of acute coronary syndrome, stroke, transient ischemic attack, pulmonary embolism, deep vein thrombosis, or arterial thromboembolism.

^¶^Other antiplatelets were cilostazol, dipyridamole, sarpogrelate hydrochloride, ethyl icosapentate, dilazep, limaprost, and beraprost.

Abbreviations: BMI, body mass index; PT-INR, prothrombin time-international normalized ratio; CHA2DS2-VASc, Congestive heart failure, Hypertension, Age ≥ 75, Diabetes mellitus, Stroke, Vascular disease, Sex female; HAS-BLED, hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, labile international normalized ratios \[INR\], elderly, drugs/alcohol concomitantly; BUN, blood urea nitrogen; NSAIDs, non-steroidal anti-inflammatory drugs; LDA, low-dose aspirin; PPIs, Proton-pump inhibitors.

Discussion {#sec016}
==========

This study presents new information on the anticoagulant management for acute GIB. First, there were no apparent differences in endoscopic results or adverse clinical outcomes of GIB between anticoagulant users and non-anticoagulant users matched for age, sex, and important risk factors as controls. Second, only patient background factors were associated with rebleeding, whereas only anticoagulant management factors (e.g. INR correction, reversal agent use, and drug interruption) were associated with thromboembolism. Only one rebleeding event and no thromboembolic events occurred in patients without reversal agent use, heparin bridge, or anticoagulant interruption. Third, some endoscopic results and clinical outcomes differed between DOAC and warfarin users or between those with upper and lower GIB.

In agreement with our findings, Choudari et al\[[@pone.0183423.ref005]\] found no significant differences in endoscopy therapy need or rebleeding between anticoagulant users and non-anticoagulated users. Konstanticos et al\[[@pone.0183423.ref006]\] reported differences in transfusion need and mortality between anticoagulant users and non-matched controls with upper GIB. Our study also showed a similar rate of early endoscopy, detailed etiology of GIB, and endoscopy-related adverse events (0%) between the two groups, suggesting that early endoscopy can be safe for anticoagulated as well as non-anticoagulated GI bleeders.

The ASGE guideline recommends that INR \< 2.5 is reasonable to perform endoscopic therapy\[[@pone.0183423.ref002]\]; however, the evidence for this is not well established. We found here that any INR category level---including INR ≥ 2.5---and a continuous INR value were not significant risk factors for rebleeding. Wolf et al\[[@pone.0183423.ref008]\] showed that neither a continuous INR value nor INR category was a predictor of rebleeding. Rubin et al\[[@pone.0183423.ref025]\] found that the rebleeding rate in patients with supratherapeutic INR (≥ 4.0) were not significantly different from those with INR 2.0--3.9. Taken together with our results, endoscopy in acute GIB would appear to be effective even in patients with elevated INR before the procedure. However, we found that INR ≥ 2.5 at onset was a significant predictor of thromboembolism. We believe this means that rapid correction of INR during the peri-endoscopic period in patients with INR ≥ 2.5 at onset confers increased risk. Because the ASGE guideline recommends performing endoscopic therapy in GI bleeding patients with INR \< 2.5\[[@pone.0183423.ref002]\], many physicians quickly reduce the INR level in the peri-endoscopic period, especially in patients with INR ≥ 2.5 at onset. We also speculate that it takes several days for the INR to reach therapeutic anticoagulation\[[@pone.0183423.ref026]\], during which time a hypercoagulable state may occur due to the procedure itself or drug interruption\[[@pone.0183423.ref027]\], leading to thromboembolism risk.

No data are available on the role of heparin bridge in acute GIB, and endoscopic guidelines do not mention this topic\[[@pone.0183423.ref002],[@pone.0183423.ref003]\]. In our study, heparin bridge did not significantly increase or decrease the risk of rebleeding, or thromboembolism. In a recent randomized controlled trial, the heparin bridge group experienced more major bleeding than the non-bridged group, with no difference in thromboembolism in the periprocedural period\[[@pone.0183423.ref028]\]. Therefore, heparin bridge might be ineffective in the acute GIB setting. We also had only one rebleeding event and no thromboembolic events in patients who had no reversal agent use, heparin bridge, or anticoagulant interruption. To summarize these points and the results of safe endoscopy in anticoagulant users, early endoscopy without INR correction, reversal agent use, heparin bridge, or anticoagulant interruption may be warranted for acute GI bleeders.

In our sub-analysis, DOAC users had a significantly higher rate of lower GIB and fewer received transfusions than warfarin users, and no significant differences were found between the groups in the rate of endoscopic therapy need, rebleeding, or thromboembolism. With respect to GIB outcomes, only one study (involving 13 dabigatran users and 26 warfarin users) has reported that dabigatran users had a lower rate of hypotension at baseline and a lower rate of transfusion need\[[@pone.0183423.ref013]\], similar to our findings. The reason for this remains to be elucidated, but warfarin users had a lower hemoglobin level and higher INR level at baseline, which affect blood loss, and this resulted in transfusion requirement.

Our study showed outcomes differences in anticoagulated patients between those with upper and lower GIB. Although 44% of patients used PPIs before the onset of upper GIB and all patients were administered them during their hospital stay, upper GI bleeders were associated with a higher rate of transfusion need and endoscopy therapy need than were lower GI bleeders. This finding suggests that anticoagulated GI bleeders may need to be managed differently, with upper GI bleeders handled more cautiously. Yamaguchi et al\[[@pone.0183423.ref029]\] showed that patients taking antithrombotics exhibited more severe clinical signs in upper GIB, which supports our findings.

One of the strengths of our study was the analysis of detailed clinical and endoscopic data that was collected from 314 GI bleeders. Another was that we identified a difference in the endoscopic results and clinical outcomes of the subgroup analyses of DOAC and warfarin users and of upper and lower GI bleeders. We also recognize several limitations. First, the 90-day outcome rate in anticoagulant users was 13.4% for rebleeding and 5.7% for thromboembolism in our study---similar to that of a Western study of 14%, and 4%, respectively\[[@pone.0183423.ref009]\]---but obtained with a relatively small number of subjects in this study. Second, INR correction, reversal agent use, and heparin bridging were at the discretion of the treating physicians, so further randomized controlled trials are needed to examine the role of these practices in managing acute GIB. Third, this was a single-center retrospective cohort investigation, and a prospective multicenter study is needed to generalize the results of this study.

In conclusion, endoscopy appears to be safe for anticoagulant users with acute GIB compared with non-users. Patient background factors were associated with rebleeding, whereas anticoagulant management factors (e.g. INR correction, reversal agent use, and drug interruption) were associated with thromboembolism. Early intervention without reversal agent use, heparin bridge, or anticoagulant interruption may be warranted for acute GIB.
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